Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT02489838
Official study title

Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Study summary

To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forLiver Neoplasms

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 11, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Alan Katz

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Alan Katz
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy
  • Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90)
  • surgical resection not feasible at time of initiation of pre-treatment workup -\> 6 months projected life span
  • ECOG 0-2
Reasons someone may not be able to joinExclusion criteria

previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Radiation Oncology, University of Rochester, Medical CenterRochester, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 11, 2020. Always confirm current availability with the study team.

View original record ↗